CELLKEY AI has officially launched OmicsPharm, an omics marketplace designed to provide researchers and companies with integrated access to omics and bioanalytical services as well as AI Agent-based data interpretation.

OmicsPharm connects a broad range of bioanalytical services on a single platform, including genomics, transcriptomics, proteomics, metabolomics, biopharmaceutical characterization, antibody-drug conjugate (ADC) analysis, and integrated multi-omics analysis.

By combining its network of analytical partners with AI Agents, CELLKEY AI plans to build an integrated bioanalysis environment that connects the entire process from data generation and interpretation to visualization and application.

In conventional bio-research workflows, finding analytical service providers, comparing quotes, managing experiments, receiving results, interpreting data, and preparing reports are often handled separately. OmicsPharm is designed to simplify this fragmented process by allowing researchers to select analytical services suited to their research objectives and systematically manage both the analysis process and resulting data.

A key component of OmicsPharm is its Agentic AI architecture, which CELLKEY AI plans to use to improve AI Agent performance based on data accumulated through the analysis process.

The platform is being structured to connect analytical service execution with data accumulation, normalization, quality assessment, and ongoing Agent performance improvement, with the aim of enhancing data utilization as more analyses are conducted.

To date, CELLKEY AI has provided more than 1,000 analytical services to over 100 clients. In Korea, the company has built experience working with organizations including Yuhan Corporation, LG Chem, Alteogen, Seoul National University Hospital, Severance Hospital, and Samsung Medical Center.

Internationally, CELLKEY AI has conducted analytical projects with institutions including Massachusetts General Hospital (MGH), a Harvard Medical School teaching hospital, the Carver College of Medicine at the University of Iowa, and Weill Cornell Medicine-Qatar. In Japan, the company is currently conducting a proof of concept (PoC) with Kyoto University’s Center for iPS Cell Research and Application (CiRA).

Going forward, CELLKEY AI plans to expand OmicsPharm into an Agentic AI-based marketplace for bioanalysis and data distribution. The company aims to develop the platform into a data hub that connects the generation, normalization, and interpretation of biological data for applications in drug discovery and precision medicine.